8-K: Tivic Health Advances Non-Invasive Vagus Nerve Stimulation with IRB Approval for Optimization Study

Tivic Health has received approval from The Feinstein Institutes Institutional Review Board to begin the next phase of clinical work on its non-invasive cervical vagus nerve stimulation (ncVNS) technology.

Summary

• Tivic Health has secured approval from The Feinstein Institutes Institutional Review Board for the next stage of clinical research into its non-invasive cervical vagus nerve stimulation (ncVNS) technology.
• This study aims to optimize stimulation parameters, including electrode positioning and electrical waveform, to enhance device performance.
• The data from this study will inform the selection of clinical populations and the design of future clinical trials.
• Tivic Health has partnered with Fletcher Spaght to identify clinical applications for its ncVNS system.
• The company is taking an integrated approach to clinical, product development, and go-to-market planning for its medical-grade non-invasive VNS program.
• The global vagus nerve stimulation market is estimated to reach $21.3 billion by 2030, growing at a CAGR of 10.6% from a value of $8.59 billion in 2021.

Sentiment

Score: 7

Explanation: The document is positive due to the IRB approval and market growth projections, but it also includes standard risk disclosures, resulting in a moderately positive sentiment.

Positives

• The IRB approval allows Tivic Health to move forward with critical research to optimize its ncVNS technology.
• The collaboration with The Feinstein Institute and Fletcher Spaght indicates a strong focus on clinical validation and market strategy.
• The projected growth of the vagus nerve stimulation market presents a significant opportunity for Tivic Health.
• The company's integrated approach to clinical, product development, and go-to-market planning is a positive sign for future success.

Risks

• The company's future results are subject to risks and uncertainties, including changes in relationships with partners, business strategy, and the timing of clinical trials.
• The company's ability to secure additional working capital when needed is a risk factor.
• The forward-looking statements are based on assumptions that may not prove to be accurate.

Future Outlook

Tivic Health anticipates moving from proof-of-concept to disease-specific validation in clinical trials next year, and aims to establish itself as a market leader in bioelectronic medicine.

Management Comments

• Jennifer Ernst, CEO of Tivic Health, stated that the integrated approach to clinical, product development, and go-to-market planning creates the best opportunities to generate significant new revenue.
• Dr. Blake Gurfein, Tivic Health's Chief Scientific Officer, commented that precision optimization is an important step in non-invasive neurostimulation device development and is pleased to be working with Dr. Zanos.

Industry Context

The announcement aligns with the growing interest and investment in bioelectronic medicine and non-invasive neuromodulation therapies, as the global vagus nerve stimulation market is projected to grow significantly.

Comparison to Industry Standards

• The projected 10.6% CAGR for the vagus nerve stimulation market is a strong indicator of the industry's growth potential, which is in line with other emerging medical technology sectors.
• Companies like LivaNova and ElectroCore are established players in the VNS market, primarily focusing on implantable devices, while Tivic Health is focusing on non-invasive solutions, which could provide a competitive advantage.
• The collaboration with The Feinstein Institute, a leading research institution, is comparable to other medical device companies partnering with academic centers for clinical validation and research.

Stakeholder Impact

• Shareholders may view the IRB approval and market growth projections positively.
• Employees may be encouraged by the progress in clinical development.
• Customers may benefit from the development of more personalized and effective treatment options.
• Suppliers may see increased demand for components used in the ncVNS device.
• Creditors may view the company's progress as a positive sign of future revenue potential.

Next Steps

• Tivic Health will conduct the optimization study with The Feinstein Institute of Bioelectronic Medicine.
• The company will use the study data to inform the selection of clinical populations and design future clinical trials.
• Tivic Health will continue to work with Fletcher Spaght to identify clinical applications for its ncVNS system.
• The company anticipates moving to disease-specific validation in clinical trials next year.

Key Dates

Keywords

vagus nerve stimulation, bioelectronic medicine, clinical trials, non-invasive, ncVNS, medical device, neuromodulation, Feinstein Institute, Fletcher Spaght